Salvianolic acid B inhibits platelets as a P2Y(12) antagonist and PDE inhibitor: Evidence from clinic to laboratory
文献类型：期刊论文
| 作者 | Liu, L; Li, J; Zhang, Y; Zhang, SH; Ye, JQ; Wen, ZC; Ding, JP; Kunapuli, SP; Luo, XP; Ding, ZR |
| 刊名 | THROMBOSIS RESEARCH
 |
| 出版日期 | 2014 |
| 卷号 | 134期号:4页码:866-876 |
| 关键词 | acute coronary syndrome antiplatelet P2Y(12) receptor antagonist phosphodiesterase inhibitor salvianolate |
| 通讯作者 | Luo, XP (reprint author), Fudan Univ, Shanghai Med Coll, Dept Cardiol, Shanghai 200040, Peoples R China.,luoxp2007@yahoo.com.cn ; dingzr@fudan.edu.cn |
| 英文摘要 | Salviae miltiorrhiza (Danshen) has been used for thousands of years in China and some other Asian countries to treat atherothrombotic diseases. Salvianolate which consists of three water-soluble ingredients purified from Salviae miltiorrhiza, has been approved by Chinese SFDA to treat coronary artery disease. So far, there is no evidence clearly showing the clinical efficiency of salvianolate and the underlying mechanism. This study is to evaluate the effects of salvianolate on platelets in patients with acute coronary syndrome and explore the underlying mechanism. We evaluated the effects of salvianolate on platelets in patients with acute coronary syndrome by measuring ADP-induced PAC-1 binding and P-selectin expression on platelets. Salvianolate significantly potentiated the antiplatelet effects of standard dual antiplatelet therapy. We also investigated the antiplatelet effects of salvianolatic acid B (Sal-B), the major component which composes 85% of salvianolate. Sal-B inhibits human platelet activation induced by multiple agonists in vitro by inhibiting phosphodiesterase (PDE) and antagonizing P2Y(12) receptor. For the first time, we show the antiplatelet efficiency of salvianolate in ACS patients undergoing treatment with clopidogrel plus aspirin, and demonstrate that Sal-B, the major component of salvianolate inhibits human platelet activation via PDE inhibition and P2Y(12) antagonism which may account for the clinical antiplatelet effects of salvianolate. Our results suggest that Sal-B may substitute salvianolate for clinical use. (C) 2014 Elsevier Ltd. All rights reserved. |
| 学科主题 | Hematology; Cardiovascular System & Cardiology |
| 类目[WOS] | Hematology ; Peripheral Vascular Disease |
| 关键词[WOS] | TRIPLE ANTIPLATELET THERAPY ; PERCUTANEOUS CORONARY INTERVENTION ; ELEVATION MYOCARDIAL-INFARCTION ; ELUTING STENT IMPLANTATION ; FLOW-CYTOMETRIC ANALYSIS ; VASP PHOSPHORYLATION ; ACTIVATION ; RECEPTOR ; AGGREGATION ; CILOSTAZOL |
| 收录类别 | SCI |
| 语种 | 英语 |
| WOS记录号 | WOS:000342360900018 |
| 版本 | 出版稿 |
| 源URL | [http://202.127.25.143/handle/331003/172]  |
| 专题 | 上海生化细胞研究所_上海生科院生化细胞研究所 |
| 推荐引用方式 GB/T 7714 | Liu, L,Li, J,Zhang, Y,et al. Salvianolic acid B inhibits platelets as a P2Y(12) antagonist and PDE inhibitor: Evidence from clinic to laboratory[J]. THROMBOSIS RESEARCH,2014,134(4):866-876. |
| APA | Liu, L.,Li, J.,Zhang, Y.,Zhang, SH.,Ye, JQ.,...&Ding, ZR.(2014).Salvianolic acid B inhibits platelets as a P2Y(12) antagonist and PDE inhibitor: Evidence from clinic to laboratory.THROMBOSIS RESEARCH,134(4),866-876. |
| MLA | Liu, L,et al."Salvianolic acid B inhibits platelets as a P2Y(12) antagonist and PDE inhibitor: Evidence from clinic to laboratory".THROMBOSIS RESEARCH 134.4(2014):866-876. |
入库方式： OAI收割
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。